Cytokine networks in the tumor microenvironment: nanotherapeutic modulation of immune-cell communication and signaling networks

Cancer remains a leading global mortality cause, driven by complex interactions within the tumor microenvironment (TME) that facilitate progression, immune evasion, and therapeutic resistance. Cytokines form the central regulatory network governing TME intercellular communication, exerting highly context-dependent pro- and anti-tumorigenic effects. Dysregulated cytokine signaling drives chronic inflammation and immunosuppression, limiting durable therapeutic responses. While cytokine-based immunotherapies show clinical potential, their widespread use is hindered by poor stability, rapid clearance, limited specificity, and dose-limiting toxicities. Advances in nanomedicine offer innovative solutions by improving cytokine pharmacokinetics, tumor-selective delivery, and spatiotemporally controlled release. Beyond passive delivery, engineered nanoplatforms act as active modulators of the tumor immune ecosystem, remodeling cytokine networks to restore antitumor immunity. Nanotechnology interventions effectively regulate key signaling pathways- including JAK/STAT, TGF-β/SMAD, NF-κB, MAPK/ERK, and PI3K/AKT- disrupting pathological feedback mechanisms and crosstalk. Furthermore, localized cytokine delivery, gene silencing, mRNA therapeutics, and CRISPR-enabled genome engineering are expanding precision immunotherapy. Despite significant translational challenges such as tumor heterogeneity, biological barriers, immunogenicity, and manufacturing complexity emerging biomimetic and personalized nanoplatforms offer promising avenues for precise immune modulation and biomarker-guided patient stratification. Literature searches were conducted across PubMed, Web of Science, Scopus, and ScienceDirect (with Google Scholar for citation tracking) covering peer-reviewed publications from 2003 to 2026.